In all the patients, the median age was 61 (ranged from 40 to 83 years); 52 were males and 56 were females; 63 were never smokers and 45 were current or former smokers; three were non-adenocarcinoma and 105 were adenocarcinoma; 57 patients harbored a 19Del mutation and 51 harbored a L858R mutation; and 87 patients received EGFR-TKI as the first-line therapy, 20 patients received EGFR-TKI as the second line therapy, and 1 received EGFR-TKI as the third-line therapy. The gene discussed is EGFR; the disease is adenocarcinoma.